|会社名||CareDx Inc （ケアディ―エックス）|
|分野（sector）||Health Care ヘルスケア|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 CareDx（CareDx Inc.）は市場を開発し、心臓移植レシピエントのための診断監視ソリューションの提供を通じて、患者の寿命を通してパーソナライズされた治療の意思決定を行うために、医者を支援する商業段階の会社である。同社のAlloMap心臓移植分子検査は、急性細胞性拒絶反応のための心臓移植レシピエントを監視するために使用される血液ベースのテストである。AlloMapは国際心臓と肺移植協会（ISHLT）の非乳児の心臓移植拒絶反応の監視のための患者ケア・ガイドラインの中に、勧められる非侵襲的方法である。同社は臓器移植レシピエントのための診断監視テスト・ソリューションを開発・提供する。その商用テスト・ソリューションAlloMapは、拒絶反応のリスクが低い心臓移植レシピエントの識別を支援するために、遺伝子発現技術を使用する。 ケアディ―エックスは、米国の医療機器ソリュ―ションの開発会社。臨床医が患者の生涯を通じて個々に応じた治療の意思決定を支援するために、心臓移植患者の診断・監視するソリュ―ションを開発、マ―ケティング、供給する。同社が最初に商品化した製品「AlloMap」は、心臓移植患者の急性細胞性拒絶を監視するために使われる血液ベ―スの検査製品である。 CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients.|
|本社所在地||3260 Bayshore Boulevard Brisbane CA 94005 USA|
|代表者氏名||Michael D. Goldberg マイケル・D・ゴールドバーグ|
|代表者役職名||Independent Chairman of the Board|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 CareDx Inc revenues increased 35% to $31.9M. Net loss increased from $9.5M to $23M. Revenues reflect Post-Transplant segment increase of 50% to $24.9M North America segment increase of 47% to $27.3M. Higher net loss reflects Pre-Transplant segment loss increase of 2% to $4.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.45 to -$0.70.|
Caredx Inc Shares Close in on 52-Week Low - Market Mover 2022/01/09 12:34:27 Kwhen Finance
Caredx Inc (CDNA) shares closed today at 1.7% above its 52 week low of $38.43, giving the company a market cap of $2B. The stock is currently down 14.1% year-to-date, down 51.6% over the past 12 months, and up 1341.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 11.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 84.3% The company's stock price performance over the past 12 months beats the peer average by -8.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to email@example.com. © 2020 Kwhen Inc.
CareDx Successfully Completes CLIA Validation of AlloMap Kidney in Preparation for Commercial Launch 2022/01/06 12:00:00 Benzinga
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ: CDNA ) The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated, healthcare solutions for transplant patients and caregivers today announced the successful completion of the Clinical Laboratory Improvement Amendments (CLIA) validation for AlloMap® Kidney, a blood-based gene expression classifier that identifies immune quiescence, an important biomarker needed to comprehensively assess immunological risk of rejection and allograft health. In clinical validation, published in Kidney360 , AlloMap Kidney demonstrated the ability to differentiate between rejection (both T-cell mediated rejection [TCMR] and antibody-mediated rejection [AMR]) and immune quiescence, and provide an assessment of immunological activity additive to the allograft injury information derived from AlloSure Kidney donor-derived cell-free DNA (dd-cfDNA), with a combined area under the curve (AUC) of 0.894. 1 Together, these two biomarkers offer a more comprehensive assessment of kidney health compared to the current standard of care.
Brokerages Set CareDx, Inc (NASDAQ:CDNA) Target Price at $97.60 2021/12/23 17:42:42 Transcript Daily
Shares of CareDx, Inc (NASDAQ:CDNA) have been assigned a consensus recommendation of Buy from the eight research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and one has issued 
Lost Money in CareDx, Inc.? 2021/12/16 23:49:00 Business Wire
OAKLAND, Calif.--(BUSINESS WIRE)---- $CDNA #CDNA--Gibbs Law Group is investigating potential legal claims on behalf of CareDx investors.
CareDx Enrolls First Patient in LungCare Registry Study to Measure Impact of Multimodality Assessment on Lung Transplant Patient Outcomes 2021/12/16 12:00:00 Intrado Digital Media
1,000 Patient ALAMO Study will Evaluate the Clinical Utility of LungCare to Detect Transplant Infection and Rejection 1,000 Patient ALAMO Study will Evaluate the Clinical Utility of LungCare to Detect Transplant Infection and Rejection
CMS clarification a boon for CareDx as Craig-Hallum reiterates buy rating 2021/07/15 15:13:43 Seeking Alpha
CareDx to Report Second Quarter 2021 Financial Results 2021/07/15 11:00:00 Intrado Digital Media
SOUTH SAN FRANCISCO, Calif., July 15, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the second quarter 2021 after market close on Thursday, July 29, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Covid-19 impact on Transplant Diagnostics Market 2026: Overview including Key Players, Drivers and Applications 2021|BD, Biofortuna, BiomÃ©rieux SA, Bio-Rad Laboratories, Caredx 2021/07/14 11:12:24 Tramways Monthly
Report Hive Research Market Reports has recently published a market research report titled, Transplant Diagnostics Market Size, Status and Forecast 2021-2026. Analysts have used primary and secondary research methodologies to determine the path of the market. The data includes historic and forecast values for a well-rounded understanding. It is a phenomenal compilation of important 
HLA Typing for Transplant Market 2021 Prominent Players: Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands), Illumina (US), CareDx, Inc. (US) 2021/07/10 17:56:28 Tramways Monthly
HLA Typing for Transplant Market by Technology (PCR (SSO, SSP, Real Time), Sequencing (NGS, Sanger)), Product (Instrument, Reagent, Software), Application (Chimerism, Antibody Screening), End User (Hospital, Diagnolab, Academia) Global Forecast to 2025 Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=3031601 The global HLA typing for 
Cell-Free DNA (cfDNA) Testing Market Accelerating CAGR +26% by 2021-28| Quest Diagnostics, Illumina, Agilent, Guardant Health, Biodesix, Allenex AB, Roche Holdings AG, Sequenom, Biocept, CareDx 2021/07/08 12:21:45 OpenPR
The Cell-Free DNA (cfDNA) Testing Market is anticipated to reach USD 22.41 Billion, capturing a CAGR of +26% by the end of 2028. Cell-free DNA (or cfDNA) refers to all non-encapsulated DNA in the bloodstream. A portion of that cell-free DNA
CareDx Strengthens Bioinformatics Capabilities with Acquisition of BFS Molecular 2021/03/17 11:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the…
Exclusive: New CareDX CEO Reg Seeto Talks Transplantation Care Provider's Mission, Vision, Growth Drivers 2021/02/23 12:50:25 Benzinga
Benzinga recently spoke with CareDx Inc (NASDAQ: CDNA ) CEO Reginald Seeto to discuss the diagnostics surveillance solution provider's business, financials, market opportunity, alliances and future focus areas. Seeto, a pharma industry veteran, took over the reins in November from then-CEO Peter Haag, who transitioned to the role of executive chairman to the board. The company is set to report fourth-quarter results after the close Wednesday. BZ: Tell us what CareDx means for the transplant community and give a brief description about its major projects and other business lines. Seeto: CareDx has been supporting transplant for more than 20 years. We are the largest dedicated transplant company in the U.S. and also in the world. It's 100% focus is on transplant. In terms of mission, it is how to improve outcomes, and our vision is to be the leader connecting the different parts of the ecosystem. We play a very important role because transplant is an area, historically, where many companies have come in and out, and I think for us we're absolutely committed to this space and supporting that patient journey.
CareDx to Report Fourth Quarter and Full Year 2020 Financial Results - Stocks News Feed 2021/02/12 12:00:00 Stocks News Feed
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Wednesday,… Read More »CareDx to Report Fourth Quarter and Full Year 2020 Financial Results
CareDx Announces Proposed Public Offering of Common Stock 2021/01/19 16:14:00 Benzinga
SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a leading precision medicine company focused on the discovery, …
Sasha King Sells 9,875 Shares of CareDx, Inc (NASDAQ:CDNA) Stock 2021/01/17 12:14:41 Watchlist News
CareDx, Inc (NASDAQ:CDNA) insider Sasha King sold 9,875 shares of the stock in a transaction on Thursday, January 14th. The stock was sold at an average price of $87.55, for a total value of $864,556.25. Following the transaction, the insider now directly owns 44,264 shares in the company, valued at approximately $3,875,313.20. The transaction was […]
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 ケアディ―エックス CDNA CareDx Inc.）